NAP-2/CXCL7
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P02775 |
---|---|
Species | Human |
Sequence | Ala59-Asp128 |
Purity | > 98% as analyzed by SDS-PAGE |
Endotoxin Level | < 0.2 EU/ µg of protein by gel clotting method |
Biological Activity | The EC50 value of human NAP-2/CXCL7 on Ca2+ mobilization assay in CHO-K1/Ga15/hCXCR1 cells (human Ga15 and human CXCR1 stably expressed in CHO-K1 cells) is less than 0.1 µg/ml. |
Expression System | CHO |
Formulation | Lyophilized after extensive dialysis against PBS. |
Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 µg/ml. |
Storage & Stability | Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
Gene ID | 5473 |
---|---|
Other Names | Platelet basic protein, PBP, C-X-C motif chemokine 7, Leukocyte-derived growth factor, LDGF, Macrophage-derived growth factor, MDGF, Small-inducible cytokine B7, Connective tissue-activating peptide III, CTAP-III, LA-PF4, Low-affinity platelet factor IV, TC-2, Connective tissue-activating peptide III(1-81), CTAP-III(1-81), Beta-thromboglobulin, Beta-TG, Neutrophil-activating peptide 2(74), NAP-2(74), Neutrophil-activating peptide 2(73), NAP-2(73), Neutrophil-activating peptide 2, NAP-2, TC-1, Neutrophil-activating peptide 2(1-66), NAP-2(1-66), Neutrophil-activating peptide 2(1-63), NAP-2(1-63), PPBP, CTAP3, CXCL7, SCYB7, TGB1, THBGB1 |
Target Background | Neutrophil Activating Peptide 2 (NAP-2) is proteolytically processed carboxyl-terminal fragments of platelet basic protein (PBP) which is found in the alpha-granules of human platelets. NAP-2 is a member of the CXC chemokines. Similar to other ELR domain containing CXC chemokines such as IL-8 and the GRO proteins, NAP-2 has been shown to bind CXCR-2 and to chemoattract and activate neutrophils. Although CTAP-III, β-TG and PBP represent amino-terminal extended variants of NAP-2 and possess the same CXC chemokine domains, these proteins do not exhibit NAP-2 activity. Recently, it has been shown that the additional amino-terminal residues of CTAP-III masks the critical ELR receptor binding domain that is exposed on NAP-2 and may account for lack of NAP-2 activity. |
Name | PPBP |
---|---|
Synonyms | CTAP3, CXCL7, SCYB7, TGB1, THBGB1 |
Function | LA-PF4 stimulates DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and synthesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by human synovial cells. NAP-2 is a ligand for CXCR1 and CXCR2, and NAP-2, NAP-2(73), NAP-2(74), NAP-2(1-66), and most potent NAP-2(1-63) are chemoattractants and activators for neutrophils. TC-1 and TC-2 are antibacterial proteins, in vitro released from activated platelet alpha-granules. CTAP-III(1-81) is more potent than CTAP-III desensitize chemokine-induced neutrophil activation. |
Cellular Location | Secreted. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.